HOME >> MEDICINE >> NEWS
Genetic variant reduces immune response, yet protects against atherosclerosis

DURHAM, N.C. -- An international team led by Duke University Medical Center researchers has discovered that a genetic variant of an immune system receptor appears to simultaneously dampen the body's immune response to bacteria and other microbial toxins and to provide some protection against atherosclerosis, or clogging of the arteries. The scientists believe their discovery suggests a possible new approach to anti-atherosclerosis drugs.

The genetic variant, or polymorphism, occurs in one of a family of 10 receptors known collectively as "Toll-like receptors" (TLRs), reflecting the fact that the human receptors resemble Toll receptors first discovered in flies. These TLRs -- which are located on the surface of immune cells, heart muscle cells, airway epithelial cells and cells lining blood vessels -- are crucial to immune responses to bacteria. They recognize a specific lipid on the surface of bacteria and provide the first warning to the immune system that an invader is present. The researchers estimate that the polymorphism of the Toll-like receptor 4 (TLR4) they studied occurs in about 10 percent of the population.

"This particular polymorphism appears to attenuate the receptor signaling ability and to diminish the inflammatory response. Our results suggest that the diminished inflammatory response is responsible for a decreased risk of atherosclerosis," said Duke's David Schwartz, M.D., principal investigator for the study, the results of which were published today (July 18, 2002) in the New England Journal of Medicine. "We were quite encouraged that the data were so compelling in the degree to which this polymorphism is so protective.

"This represents a completely new mechanism involved in atherosclerosis and cardiovascular disease, and it provides a potential novel target for decreasing one's chances of developing heart disease," Schwartz continued. "In addition to using traditional means to reduce the risk of heart disease, such as ex
'"/>

Contact: Richard Merritt
merri006@mc.duke.edu
919-684-4148
Duke University Medical Center
17-Jul-2002


Page: 1 2 3

Related medicine news :

1. Genetics important in age-related macular degeneration
2. Genetic amplification (NAAT) test detects HIV more effectively than standard tests in urban study
3. Genetically targeted therapies create opportunities to do business in new ways
4. Genetic testing can identify ischemic and nonischemic heart failure
5. Genetics testing saves health care dollars
6. Genetic mutation linked to infant lung disease
7. Genetic switch proves two mechanisms exist by which immune system cells differentiate
8. Genetic risks for disease often missing from patient charts
9. Genetics of familial atrial fibrillation revealed, Science researchers report
10. Genetic variant may impact smoking cessation
11. Genetics in clinical practice: a revolutionary approach

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/21/2017)... ... January 21, 2017 , ... Pacifica Graduate Institute’s Alumni ... line-up of events for its annual meeting “Coming Home 2017,” an activity-packed weekend ... Home 2017” will be held on Friday January 27 through Sunday, January 29, ...
(Date:1/21/2017)... ... January 21, 2017 , ... The Nobel Biocare™ ... Holtzclaw in media for its creos™ line of bone regenerative products. Specifically, ... in which he utilizes creos™ allo.gain™ bone graft for a variety of bone ...
(Date:1/20/2017)... ... ... Source Vitál Apothecary, a skin and body care company dedicated to creating ... a successful visit to the 2017 ECRM Diet, Vitamin & Sports Nutrition Conference in ... nutritional, sports and health industries a chance to meet in private sessions with some ...
(Date:1/20/2017)... ... January 20, 2017 , ... ATP ... people’s everyday lives, recently attended the January ECRM Trade Show in Hilton Head, ... known for its large range of supplements that keep the body functioning at ...
(Date:1/20/2017)... York, NY (PRWEB) , ... January 20, 2017 ... ... – VW+ 001 and its sugar-free alternative VW+ 002. The drinks have been ... body with optimal conditions to perform during your workout. , After a successful ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... -- Conference Call and Webcast to Follow Vanda Pharmaceuticals ... release results for the fourth quarter of 2016 on Wednesday, February ... ... 4:30 PM ET on Wednesday, February 15, 2017, during which management ... and other corporate activities. To participate in the conference call, please ...
(Date:1/19/2017)... 19, 2017 This report on the opioid ... scenario of the global market. Large number of chronic ... chronic constipation is a major side effect of consumption ... novel targeted therapy has been prescribed to treat opioid ... targeted medicines, and growing awareness about the therapy are ...
(Date:1/19/2017)... 2017  Stealth BioTherapeutics Inc. ( Stealth ), a ... today announced new additions to its senior leadership team: ... Officer, and Daniel Geffken as interim Chief ... Carr , Pharm.D. has been promoted to Chief Clinical ... welcome Doug and Daniel to our management team, as ...
Breaking Medicine Technology:
Cached News: